OPHTHETIC Drug Patent Profile
✉ Email this page to a colleague
When do Ophthetic patents expire, and when can generic versions of Ophthetic launch?
Ophthetic is a drug marketed by Allergan and is included in one NDA.
The generic ingredient in OPHTHETIC is proparacaine hydrochloride. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the proparacaine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ophthetic
A generic version of OPHTHETIC was approved as proparacaine hydrochloride by BAUSCH AND LOMB on September 29th, 1995.
Summary for OPHTHETIC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 47 |
Patent Applications: | 4,128 |
Formulation / Manufacturing: | see details |
DailyMed Link: | OPHTHETIC at DailyMed |
US Patents and Regulatory Information for OPHTHETIC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allergan | OPHTHETIC | proparacaine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 012583-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |